Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of

abstract：:Regulatory T cells (Tregs) facilitate primary and metastatic tumour growth through the suppression of anti-tumour immunity. Emerging evidence suggests a distinct role for Tregs in mediating tissue repair and barrier integrity in the lungs by IL-33 mediated production of the growth factor amphiregulin (AREG). Dependent...

journal_title：Oncoimmunology

authors： Halvorsen EC,Franks SE,Wadsworth BJ,Harbourne BT,Cederberg RA,Steer CA,Martinez-Gonzalez I,Calder J,Lockwood WW,Bennewith KL

更新日期：2018-10-16 00:00:00

abstract：:The instauration of an immunosuppressive microenvironment is a key event in cancer development and progression. Here, we discuss increasing evidences of the crosstalk between myeloid-derived suppressor cells (MDSCs) and mast cells (MCs) as a new fuel for the cancer immunosuppressive machinery. ...

journal_title：Oncoimmunology

authors： Danelli L,Frossi B,Pucillo CE

更新日期：2015-03-24 00:00:00

abstract：:Although high levels of tumor-infiltrating lymphocytes (TILs) generally correlate with good prognosis in high-grade serous ovarian cancer (HGSC) patients, little is known about the phenotype or specificity of these cells. We have recently demonstrated that TIL expressing the intra-epithelial lymphocyte marker CD103 (o...

journal_title：Oncoimmunology

authors： Webb JR,Milne K,Nelson BH

更新日期：2014-01-10 00:00:00

abstract：:We have made major advances in the treatment of melanoma through the use of targeted therapy and immune checkpoint blockade; however, clinicians are posed with therapeutic dilemmas regarding timing and sequence of therapy. There is a growing appreciation of the impact of antitumor immune responses to these therapies, ...

journal_title：Oncoimmunology

authors： Cooper ZA,Reuben A,Spencer CN,Prieto PA,Austin-Breneman JL,Jiang H,Haymaker C,Gopalakrishnan V,Tetzlaff MT,Frederick DT,Sullivan RJ,Amaria RN,Patel SP,Hwu P,Woodman SE,Glitza IC,Diab A,Vence LM,Rodriguez-Canales J,P

更新日期：2016-02-02 00:00:00

abstract：:DNA damage responses have been proposed as a gatekeeper to block tumorigenesis. We identify unexpected mechanisms whereby ATM-mediated pathway interacts with NFκB inflammatory cascades, leading to upregulation of integrin-αbβ3 on chemoresistant tumor cells. The integrin-αbβ3 is responsible for impeding tumor-specific ...

journal_title：Oncoimmunology

authors： Jinushi M

更新日期：2012-05-01 00:00:00

abstract：:Combination therapies with phosphoinositide 3-kinase (PI3K) inhibitors and trastuzumab (anti-human epidermal growth factor receptor [HER]2/neu antibody) are effective against HER2+ breast cancer. Isoform-selective PI3K inhibitors elicit anti-tumor immune responses that are distinct from those induced by inhibitors of ...

journal_title：Oncoimmunology

authors： Choi JH,Kim KH,Roh KH,Jung H,Lee A,Lee JY,Song JY,Park SJ,Kim I,Lee WS,Seo SK,Choi IW,Fu YX,Yea SS,Park S

更新日期：2018-01-16 00:00:00

abstract：:Recent studies of human pancreatic cancer challenge the mouse model-derived notion that the pancreas is a site of immune privilege. A heavy infiltration of CD8+ T cells expressing programmed cell death 1 (PD-1) and smaller numbers of myeloid cells and regulatory T cells provides rationale for the clinical evaluation o...

journal_title：Oncoimmunology

authors： Pillarisetty VG

更新日期：2014-08-03 00:00:00

abstract：:Interleukin-10 (IL-10) is a potent immunomodulatory cytokine, whose cellular targets have not yet been precisely identified. Dendritic cell (DC)-specific IL-10 receptor knockout mice exhibit exaggerated T-cell reactivation in the skin, highlighting a key role of DCs in the maintenance of local immune homeostasis, beyo...

journal_title：Oncoimmunology

authors： Clausen BE,Girard-Madoux MJ

更新日期：2013-03-01 00:00:00

abstract：:The immune contexture, a composition of the tumor microenvironment, plays multiple important roles in cancer stem cell (CSC) and epithelial-mesenchymal transition (EMT), and hence critically influences tumor initiation, progression and patient outcome. Tumor-associated macrophages (TAMs) are abundant in immune context...

journal_title：Oncoimmunology

authors： Li S,Xu F,Zhang J,Wang L,Zheng Y,Wu X,Wang J,Huang Q,Lai M

更新日期：2017-10-11 00:00:00

abstract：:DNA vaccination consists of administering an antigen-coding nucleotide sequence. In order to improve the efficacy of DNA vaccines, electroporation is one of the most commonly used methods to enhance DNA uptake. Here, we discuss additional immunological effects of electroporation that are key aspects for inducing immun...

journal_title：Oncoimmunology

authors： Calvet CY,André FM,Mir LM

更新日期：2014-04-29 00:00:00

abstract：:Tumor cells expressing TLRs is generally recognized to mediate tumor inflammation. However, whether and how tumor TLR signaling pathways negatively regulate tumor inflammation remains unclear. In this report, we find that TLR4 signaling of H22 hepatocarcinoma tumor cells is transduced through MyD88 pathway to actin cy...

journal_title：Oncoimmunology

authors： Li D,Jia H,Zhang H,Lv M,Liu J,Zhang Y,Huang T,Huang B

更新日期：2012-08-01 00:00:00

abstract：:Advanced ovarian cancer (OC) patients have a poor 5-year survival of only 28%, emphasizing the medical need for improved therapies. Adjuvant immunotherapy could be an attractive approach since OC is an immunogenic disease and the presence of tumor-infiltrating lymphocytes has shown to positively correlate with patient...

journal_title：Oncoimmunology

authors： Maas RJ,Hoogstad-van Evert JS,Van der Meer JM,Mekers V,Rezaeifard S,Korman AJ,de Jonge PK,Cany J,Woestenenk R,Schaap NP,Massuger LF,Jansen JH,Hobo W,Dolstra H

更新日期：2020-11-08 00:00:00

abstract：:Acute myeloid leukemia (AML) is a heterogeneous disease whose therapies currently show elevated toxicity and a high rate of relapse. Recently, the burgeoning of new anti-tumor therapeutic strategies aimed at enhancing the immune response has pushed natural killer cells (NKs) into the spotlight. These cells are powerfu...

journal_title：Oncoimmunology

authors： Baragaño Raneros A,López-Larrea C,Suárez-Álvarez B

更新日期：2018-10-31 00:00:00

abstract：:We have recently described two types of Langerhans cells (LCs), which develop via separate pathways in steady-state conditions and during inflammation. Here, we propose that these two types of LCs differ in their requirement for transforming growth factor β1 (TGFβ1), and we discuss how TGFβ1 impacts on the development...

journal_title：Oncoimmunology

authors： Seré K,Felker P,Hieronymus T,Zenke M

更新日期：2013-03-01 00:00:00

abstract：:Agonistic tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-receptor-specific antibodies are attractive antitumor therapeutics. Recently, our group has generated several human monoclonal antibodies (mAbs) to TRAIL-receptor-1 (TRAIL-R1) (TR1-IgGs) using ISAAC technology. However, these TR1-IgGs did ...

journal_title：Oncoimmunology

authors： Piao X,Ozawa T,Hamana H,Shitaoka K,Jin A,Kishi H,Muraguchi A

更新日期：2016-05-04 00:00:00

abstract：INTRODUCTION:Vaccination with dendritic cells (DCs) has generally not fulfilled its promise in cancer immunotherapy due to ineffective translation of immune responses into clinical responses. A proposed reason for this is intrinsic immune regulatory mechanisms, such as regulatory T cells (Tregs). A metronomic regimen o...

journal_title：Oncoimmunology

authors： Borch TH,Engell-Noerregaard L,Zeeberg Iversen T,Ellebaek E,Met Ö,Hansen M,Andersen MH,Thor Straten P,Svane IM

更新日期：2016-07-08 00:00:00

abstract：:Adoptive cell transfer (ACT) is an emerging anticancer therapy that has shown promise in various malignancies. Redirecting antigen specificity by genetically engineering T cells to stably express receptors has become an effective variant of ACT. A novel extension of this approach is to utilize engineered T cells to pr...

journal_title：Oncoimmunology

authors： Tsai AK,Davila E

更新日期：2016-01-15 00:00:00

abstract：:The functional status of CD4(+) T cells is a critical determinant of antitumor immunity. Polyfunctional CD4(+) T cells possess the ability to concomitantly produce multiple Th1-type cytokines, exhibiting a functional attribute desirable for cancer immunotherapy. However, the mechanisms by which these cells are induced...

journal_title：Oncoimmunology

authors： Ding ZC,Liu C,Cao Y,Habtetsion T,Kuczma M,Pi W,Kong H,Cacan E,Greer SF,Cui Y,Blazar BR,Munn DH,Zhou G

更新日期：2016-04-25 00:00:00

abstract：:Depending on tumor type, stage and immunological contexture, the inhibition of chemokines or their receptors may yield positive or deleterious effects on disease progression. We have recently demonstrated in several murine models of anthracycline-based chemotherapy that the inhibition of chemokine (C-C motif) ligand 2...

journal_title：Oncoimmunology

authors： Ma Y,Adjemian S,Galluzzi L,Zitvogel L,Kroemer G

更新日期：2014-01-01 00:00:00

abstract：:Prognosis of glioblastoma remains dismal, underscoring the need for novel therapies. Immunotherapy is generating promising results, but requires combination strategies to unlock its full potential. We investigated the immunomodulatory capacities of poly(I:C) on primary human glioblastoma cells and its combinatorial po...

journal_title：Oncoimmunology

authors： De Waele J,Marcq E,Van Audenaerde JR,Van Loenhout J,Deben C,Zwaenepoel K,Van de Kelft E,Van der Planken D,Menovsky T,Van den Bergh JM,Willemen Y,Pauwels P,Berneman ZN,Lardon F,Peeters M,Wouters A,Smits EL

更新日期：2017-12-12 00:00:00

abstract：:Chimeric antigen receptors (CARs) possess fixed specificity for a single antigen and require empirical testing in T cells. To address this, we have developed a novel, adaptable immune receptor strategy that allows for the rapid generation and testing of T cells of nearly infinite antigen specificity. ...

journal_title：Oncoimmunology

authors： Urbanska K,Powell DJ

更新日期：2012-08-01 00:00:00

abstract：:We have recently reported that the PD-1 and CTLA4 signaling pathways are active in both effector and regulatory T cells, causing profound immune dysfunctions in the tumor microenvironment. In line with this notion, the dual blockade of PD-1- and CTLA4-conveyed signals may exert robust therapeutic effects. Here, we dis...

journal_title：Oncoimmunology

authors： Duraiswamy J,Freeman G,Coukos G

更新日期：2013-10-01 00:00:00

abstract：:Synthesis of extracellular adenosine by the ectonucleotidases CD39 and CD73 represents an important pathway of immune suppression in the tumor microenvironment. Using two mouse models (RET transgenic melanoma and Panc02 orthotopic pancreatic adenocarcinoma), we identified an elevated frequency of ectonucleotidase-expr...

journal_title：Oncoimmunology

authors： Shevchenko I,Mathes A,Groth C,Karakhanova S,Müller V,Utikal J,Werner J,Bazhin AV,Umansky V

更新日期：2020-04-09 00:00:00

abstract：:Due to their constant exposure to inhaled antigens, lungs represent a particularly immunosuppressive environment that limits excessive immune responses; however, cancer cells can exploit this unique environment for their growth. We previously described the ability of aerosolized CpG-ODN combined with Poly(I:C) (TLR9 a...

journal_title：Oncoimmunology

authors： Le Noci V,Sommariva M,Tortoreto M,Zaffaroni N,Campiglio M,Tagliabue E,Balsari A,Sfondrini L

更新日期：2016-09-20 00:00:00

abstract：:The immune system avoids oncogenesis and slows down tumor progression through a mechanism called immunosurveillance. Nevertheless, some malignant cells manage to escape from immune control and form clinically detectable tumors. Tetraploidy, which consists in the intrinsically unstable duplication of the genome, is con...

journal_title：Oncoimmunology

authors： Aranda F,Chaba K,Bloy N,Garcia P,Bordenave C,Martins I,Stoll G,Tesniere A,Kroemer G,Senovilla L

更新日期：2018-05-21 00:00:00

abstract：:The achievement of malignant traits in several cancers is associated with tumor microenvironment reactivity. New evidence show that the stress hormone noradrenaline enhances melanoma microenvironment reactivity, mainly acting through β3-adrenoreceptors (β2-ARs), favoring recruitment of cancer-associated fibroblasts, M...

journal_title：Oncoimmunology

authors： Chiarugi P,Filippi L

更新日期：2015-04-02 00:00:00

abstract：:The recent findings on NK activation indicate that these cells are important antitumor effectors. NK cells participate in the graft-vs.-leukemia effect to control the relapse in leukemic patients transplanted with allogeneic hematopoietic stem cells. In various tumors, correlation between NK cell infiltrates and progn...

journal_title：Oncoimmunology

authors： Fregni G,Perier A,Avril MF,Caignard A

更新日期：2012-01-01 00:00:00

abstract：:The first study demonstrating that human colorectal carcinoma (CRC) is under robust immunosurveillance was published a decade ago. Today, it is clear that CRC patients with Stage III lesions abundantly infiltrated by effector memory T cells have a better prognosis than subjects with Stage I neoplasms exhibiting no or ...

journal_title：Oncoimmunology

authors： Kroemer G,Galluzzi L,Zitvogel L,Fridman WH

更新日期：2015-06-05 00:00:00

abstract：:Analysis of PDL1 mRNA expression in ∼5,500 breast cancers showed PDL1 upregulation in 38% of basal tumors and 38% of inflammatory breast cancers (IBC). Upregulation, associated with signs of strong cytotoxic local immune response, was associated with a better survival in the basal or triple-negative subtypes, and with...

journal_title：Oncoimmunology

authors： Bertucci F,Finetti P,Birnbaum D,Mamessier E

更新日期：2015-08-31 00:00:00

abstract：:The correlation between tumor-infiltrating lymphocyte (TIL)-expression of programmed cell death ligand 1 (PD-L1) and clinical responsiveness to the PD-1 blocking antibody nivolumab implicates adaptive immune evasion mechanisms in cancer. We review our findings that tumor cell PD-L1 expression is induced by interferon ...

journal_title：Oncoimmunology

authors： Kim YJ

更新日期：2015-01-07 00:00:00